Summary: Basic fibroblast growth factor (bFGF) is a polypeptide that promotes neuronal survival and blocks excitatory amino acid (EAA) neurotoxicity in vitro at very low concentrations. In the present study, we exam ined whether systemically administered bFGF could pre vent neuronal damage induced by either EAAs or hypox ia-ischemia in vivo. Neuroprotective effects were exam ined in a neonatal model of hypoxia-ischemia (unilateral ligation of the carotid artery followed by exposure to 8% oxygen for 1.5 h) and following intrastriatal injection of N-methyl-D-aspartate (NMDA) in 7-day-old rats. Intra peritoneal administration of a single dose of bFGF (50--300 j-lg/kg) 30 min before intrastriatal injection of NMDA showed a dose-dependent neuroprotective effect. Re peated doses of bFGF (IOO j-lg/kg) both before and after Perinatal hypoxic-ischemia brain injury is a seri ous clinical problem with severe neurological con sequences such as cerebral palsy, mental and phys ical retardation, and seizures (Nelson and Ellen berg, 1986; Torfs et aI., 1990). Recent studies have implicated excitatory amino acids (EAAs) in the pathogenesis of neuronal injury in hypoxia ischemia, hypoglycemia, seizures, and some neuro degenerative diseases (Beal et aI
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have been effective in reducing neuronal damage in experimental models of these disorders (Choi, 1990) .
Fibroblast growth factors (FGFs), first identified as polypeptides with mitogenic activity for fibro blasts in brain extracts (Gospodarowicz, 1974) , have multiple biological activities in mammalian cells (Gospodarowicz et aI., 1986; Folkman and Klagsbrun, 1987; Wagner, 1991) . Two forms of FGF, acidic and basic, are widely distributed in the immature and adult CNS (Pettmann et aI., 1986; Eckenstein et aI., 1991; Powell et aI., 1991; Gomez Pinilla et aI. , 1992) , and their receptors are also lo calized in the CNS (Heuer et aI., 1990; Wanaka et aI., 1990) . FGFs act as neurotrophic factors for sev eral neuronal populations of the CNS in vitro (Mor rison et aI. , 1986; Walicke et aI., 1986; Un sicker et aI., 1987; Hatten et aI., 1988; Walicke, 1988; Ferrari et aI., 1989; Torres-Aleman et aI. , 1990) and in vivo (Anderson et aI., 1988; Otto et aI., 1989; Otto and Unsicker, 1990; Yamada et aI., 1991) . More re-cently, basic FGF (bFGF) has been shown to pro tect against EAA-induced neurotoxicity in cultured striatal and hippocampal neurons in vitro (Mattson et aI., 1989; Mattson and Rychlik, 1990; Freese et aI., 1992) and against ischemic neuronal death in vivo when administered intraventricularly (Berlove et aI., 199 1). Although bFGF would not be expected to cross the blood-brain barrier (BBB) under ordi nary circumstances, the BBB is not fully developed in neonatal animals. In the present study, we there fore examined the effects of systemic administra tion of bFGF on neuronal damage induced by either N-methyl-D-aspartate (NMDA) or hypoxia-isch emia in 7-day-old rats.
MATERIALS AND METHODS

Animals
Pregnant Sprague-Dawley rats (Charles River Labora tories, Wilmington, MA, U.S.A.) were housed in sepa rate cages after 17-18 days of gestation under diurnal lighting conditions and allowed food and water ad libitum. Pups were born on day 21 or 22 of gestation.
NMDA neurotoxicity
On the 7th day of life, pups were removed from their mothers, kept in a temperature-controlled incubator at 37.0 ± OSC for 30 min, and then briefly anesthetized with methoxyflurane (Pitman-Moore, Mundelein, IL, U.S.A.). NMDA (25 nmol/l.O fJ.l) was injected into the left striatum as described previously with minor modifi cations (Nozaki and Beal, 1992) . Briefly, the calvarium was exposed by a midline skin incision, and pups were positioned in a plaster mold of the head and body. Intra striatal stereotaxic injection was done over I min using a Hamilton syringe with a 26-gauge needle and a microin jector. The coordinates were 0.0 mm posterior, 2.0 mm lateral, and 3.5 mm ventral to the dural surface, using the bregma as a landmark. The needle was left in place for 1 min following NMDA injection after withdrawing 0.5 mm to limit leakage up the needle tract. NMDA was dissolved in water and the pH adjusted to 7.2. The surgical proce dures took <5 min. After a 2-h recovery period, the pups were returned to their dams for 96 h before death. Re combinant human bFGF was a generous gift of Creative Biomolecules (Hopkinton, MA, U.S.A.). It was stored in 10 mM Tris/1 mM dithiothreitol/0.27 M NaCI (pH 7.4) at a concentration of 0.55 mglml at -80°C. Each batch of bFGF used was tested for biological activity by a stan dard mitogenic assay on Balb c/3T3 cells (5-10 activity units/ng). The stock solution was diluted before use in 0.1 M phosphate-buffered saline with 100 fJ. 
Hypoxia-ischemia
Hypoxia-ischemia was produced as described previ ously (Nozaki and Beal, 1992) . Seven-day-old rats were removed from their mothers, kept in a temperature controlled incubator at 37.0 ± OSC for 30 min, and then briefly anesthetized with methoxyflurane. Their right common carotid arteries were exposed through a midline neck incision, doubly ligated, and cut between the two ligatures. The operations took <5 min. After pups were return � d to the incubation for 2 h, they were exposed to hypOXia for 1.5 h (humidified 8% oxygen balanced with nitrogen) in plastic chambers warmed to and maintained at 37°C. A�ter a 3-h recovery period in the incubator, pups were permitted to survive with their dams for 96 h prior to death. Control animals received vehicle solution intra peritoneally 30 min before and 0 and 30 min after the hypoxia-ischemia. Treated animals received either 100 fJ.glkg of bFGF once 30 min before and vehicle solution 0 and 30 min after the hypoxia-ischemia or 100 fJ.glkg of ?FGF �O min before and 0 and 30 min after the hypoxia Ischemia.
Tissue preparations
Following death by decapitation, the brains were im mediately removed, placed in cold saline for 10 min and sectioned coronally into five slices at 2-mm interval� in a rodent brain matrix (Activational Systems, Warren, MI, U.S.A.). Slices were stained in 2%, 2,3,5-triphenyltetra zolium chloride monohydrate (TIC; Sigma) solution at room temperature in the dark for 30 min followed by fix ation in 10% formalin overnight (Bederson et al., 1986) . The lesion or infarct area (noted by pale staining) was measured on the posterior surface of each section (Bio qu � nt .
IV image analysis system, EVEREX computer, MtJ Vldeocamera, Sony Monitor Vision, and Olympus SZH microscope). The volumes of the lesions or infarcts and of both the ipsilateral and the contralateral hemi spheres were calculated for each slice. The measure ments of lesion, infarct, and hemispheric volume were made by an experienced histologist who was blind to the experimental conditions.
Temperature monitoring
In separate experiments, body temperature was moni tored in pups that moved freely in the incubator using a thermocouple needle probe (DP41-TC; Omega, Stanford, CT, U.S.A.). Rectal temperature was recorded in nonop erated and NMDA-injected animals for up to 3 h after the intraperitoneal injection of 100 fJ.glkg of bFGF (NMDA was injected into the left striatum as described above 30 min after the administration of bFGF) and in animals that underwent the hypoxia-ischemia for up to 3 h after the intraperitoneal injection of single or repeated doses of 100 fJ.g/kg of bFGF. Control animals received vehicle solution.
Statistics
Data are expressed as means ± SD. Statistical signifi cance of differences in lesions, infarcts, and hemispheric volumes between groups was determined by one-way analysis of variance (ANOV A) followed by the Fisher protected least significant difference (PLSD) test. Com parison of differences between hemispheric volumes ip-silateral and contralateral to the NMDA injection or ca rotid ligation was made by Student's t test. Probability values of <0.01 were considered significant.
RESULTS
NMDA neurotoxicity
NMDA (25 nmol/l.O fl1) injections into the stria tum produced consistent neuronal damage in the striatum and the overlying cortex as determined by TTC staining 96 h after the injection and a reduction in the volume of the hemisphere ipsilateral to the injection. There was no mortality (Tables 1 and 2 ; Fig. la) . Intraperitoneal administration of bFGF (50, 100, 200, 300 flg/kg) 30 min before the NMDA injections prevented the neuronal damage dose de pendently ( Table 1 ). The neuroprotective effect of 100 flg/kg of bFGF was nearly maximal with little additional effect of 200 or 300 flg/kg of bFGF. Treatment with bFGF before and after the NMDA injections showed more potent neuroprotective ef fects (Table 2 ; Fig. Ib) . Repeated administration of bFGF three times before and after the NMDA in jections (100 flg/kg x 3) reduced lesion volume by 64% (p < 0.001 as compared with vehicle group), which was significantly more effective than a single administration of 300 flg/kg of bFGF (p = 0.009).
Hypoxia-ischemia
In the vehicle-treated group, 30 of 43 pups (70%) survived the hypoxic-ischemia insult and 21 of 30 pups (70%) showed macroscopic neuronal injuries in the cerebral cortex, striatum, and hippocampus ipsilateral to the carotid ligation as determined by TTC staining 96 h after the insult (Table 3 ; Fig. 2a ). The hemisphere ipsilateral to the carotid ligation was significantly reduced in volume as compared with the contralateral side (Table 3 ; Fig. 2a ). Intra peritoneal administration of bFGF (100 flg/kg x lor 100 flg/kg x 3) did not change the survival rate but dose dependently reduced the infarct rate and in farct volume and prevented the reduction in ipsilat- eral hemisphere volumes (Table 3) . Three repeated injections of bFGF during the perihypoxic period reduced the infarct volume by 64% (p = 0.004 as compared with vehicle group) (Table 3; Fig. 2b ). or vehicle solution were not significantly different between groups in nonoperated or NMDA-injected animals (Table 4) . Rectal temperatures measured for 3 h after intraperitoneal administrations of single or repeated doses of 100 J.Lg/kg of bFGF or vehicle solution were not also significantly different be tween groups in hypoxic-ischemia animals (Ta ble 4).
DISCUSSION
FGFs are members of the family of heparin bind ing protein growth factors that have a wide variety of biological activities in mammalian cells (Gospo darowicz et aI., 1986 (Gospo darowicz et aI., , 1987 Folkman and Klags brun, 1987; Wagner, 1991) . Recent studies suggest that FGFs may play an important role in the devel opment and maintenance of the nervous system. FGFs are present in relatively high levels in brain (Gospodarowicz et aI. , 1987; Burgess and Maciag, 1989 ) and probably are the major mitogenic factors extracted from developing and adult brains (Thom as, 1987; Powell et aI. , 1991) . They promote the survival and neurite outgrowth of cultured neurons from the cerebral cortex (Morrison et aI. , 1986; Un sicker et aI. , 1987; Hatten et aI. , 1988), hippocam pus (Walicke et aI., 1986; Needels and Cotman, 1988) , striatum (Walicke, 1988) , thalamus (Walicke, 1988) , cerebellum (Hatten et aI. , 1988), and periph eral ganglia (Schubert et aI., 1987; Unsicker et ai, 1987; Eckenstein et aI. , 1990) . FGFs also act as potent mitogens in vitro for astrocytes (Pettmann et aI., 1985) , oligodendrocytes (Eccleston and Silber berg, 1985) , and Schwann cells (Davis and Stroobant, 1990) . bFGF has more potent neuro trophic effects than acidic FGF (Walicke, 1988) and has been shown to rescue both septal and retinal ganglion neurons from retrograde degeneration in vivo (Sievers et aI. , 1987; Anderson et aI., 1988; Otto et aI., 1989) . It also has neuroprotective effects against I-methyl-4-phenyl-l ,2,3 ,6-tetrahydropyri dine-induced dopaminergic neurotoxicity in mice (Otto and Unsicker, 1990) .
In the present study we demonstrate for the first son et al., 1988; Otto et al. , 1989; Berlove et al., 1991; Hara et aI. , 1991; Yamada et aI. , 1991) . In the present study we reasoned that systemic adminis tration of bFGF might prove effective in neonatal animals since their BBB is not fully developed (Ri sau and Wolburg, 1990) and both hypoxia-ischemia and excitotoxic lesions can result in impairment of the BBB (Nakagawa et aI. , 1990). We initially ex amined the effects of increasing doses of bFGF on NMDA-induced excitotoxic damage. Increasing doses of bFGF produced dose-dependent neuropro tection, with a nearly maximal effect seen with a dose of 100 J-Lg/kg. Increasing the dose to 200 or 300 J-Lg/kg produced little additional benefit. We there fore examined the effects of repeated dosing with bFGF at 100 J-Lg/kg. Doses were administered at 30-min intervals both before and after intrastriatal NMDA injections. This dosing regimen resulted in increasing neuroprotection with one, two, or three doses of bFGF. The maximal effect with three doses was a 64% reduction in the volume of the lesion. We therefore examined the effects of either a single dose or three doses of 100 J-Lg/kg of bFGF on hypoxic-ischemic neuronal damage. The admin istration of a single dose reduced the infarct volume by 38%, which was not quite significant; however, three doses reduced the infarct volume significantly by 64%. The effects did not appear to be due to hypothermia, since administration of bFGF to neo natal animals had no effect on rectal temperature for up to 3 h. A recent study has shown that the intravenous administration of FGFs results in po tent vasodilatory effects through endothelium derived relaxing factors and ATP-dependent K + channels (Cuevas et aI. , 1991). These effects result in hypotension, which would be expected to exac erbate neuronal injury. It is therefore possible that the true magnitude of the neuroprotective effect was partially masked. One prior study found no sig nificant effect of a single local administration of bFGF on delayed neuronal death induced by tran sient forebrain ischemia in adult rats (Hara et al., 1991) . The study of Berlove et aI., (1991), however, showed that continuous intraventricular administra tion of bFGF for 3 days before and 7 days after global ischemia in gerbils significantly protected against hippocampal cell losses.
The present results are in accordance with in vitro studies showing that bFGF can exert neuro protective effects against both glutamate-and hy poglycemia-induced neurotoxicity in cultured neu ronal cells (Mattson et aI. , 1989; Cheng and Matt son, 1991; Freese et aI. , 1992) . Mattson et aI. (1989) showed that FGFs (containing both acidic FGF and bFGF) raised the threshould for glutamate neu rotoxicity and reduced glutamate-induced rises in intracellular calcium levels in rat hippocampal cell cultures. In their studies protective effects of FGFs against glutamate neurotoxicity required pretreat ment with FGFs for several hours, and the effects of FGFs were blocked by pretreatment with either RNA or protein synthesis inhibitors. These results suggest that FGFs antagonize glutamate-induced rises in intracellular calcium by a mechanism re quiring protein synthesis. In subsequent work Cheng and Mattson (1991) showed that both nerve growth factor (NGF) and bFGF prevented hypogly cemia-induced neuronal degeneration in human ce rebral cortical and rat hippocampal cell cultures. Both growth factors prevented hypoglycemia induced increases in intracellular calcium. The neu roprotective effects of bFGF occurred in the 10-100 pM range, which is in the range of concentrations that exert trophic effects at the bFGF receptor. Freese et ai. (1992) showed that bFGF prevented neurotoxicity induced by glutamate and quinolinate (NMDA receptor agonists) but not kainate (non NMDA receptor agonist) in neonatal rat striatal neurons, which implies that bFGF may act against NMDA receptors more effectively than non-NMDA receptors. Hypoxic-ischemic brain damage in neonatal rats is mediated primarily by NMDA receptors (McDonald et aI., 1988; Ikonomidou et aI., 1989) , and bFGF exerts potent neuroprotective effects against hypoxia-ischemia and NMDA exci totoxicity, as shown in the present study.
The precise site of neuroprotective effects of bFGF in vivo is unknown. The effects of bFGF may be mediated either directly on neurons or indirectly via astroglial cells. Recent studies show that bFGF can be released from astroglia, microglia, and hip pocampal neurons in vitro (Araujo and Cotman, 1992) . The release from astroglia was enhanced by interleukin-l, interleukin-6, and epidermal growth factor; however, no effects were seen in neuronal cultures. FGFs are thought to act via their specific receptors (Ruta et aI., 1988; Lee et aI., 1989; Fer guson and Johnson, 1991) , which are widely distrib uted in both the immature and the adult CNS (Heuer et aI., 1990; Wanaka et aI., 1990) . In the adult brain, high levels of FGF receptors are found in neurons of the hippocampus, brainstem, cerebel lum, and spinal cord. A recent in vitro study showed that bFGF has direct trophic effects on neu rons that are not mediated via glial cells (Unsicker et aI., 1992) . Cortical neurons have moderate levels of FGF receptors; however, FGF receptors have not been localized to striatal neurons. This appears paradoxical since Walicke (1988) showed that bFGF promotes survival of cultured striatal neu rons. The situation may be analogous to NGF, which exerts neuroprotection against striatal exci totoxic lesions in vivo (Aloe, 1987; Schumacher et aI., 1991) despite an apparent absence of NGF re ceptors in this region (Dawbarn et aI., 1988; Koh et aI., 1989) . Nevertheless, the paucity of bFGF re ceptors in this region raises the possihility that the neuroprotective effects of bFGF may be mediated by glial cells. bFGF does enhance the survival and growth of glial cells (Eccleston and Silberberg, 1985; Pettman et aI., 1985) and increases the expres sion of glial cell markers such as glial fibrillary acidic protein, glutamate synthetase, and S100 pro tein (Morrison et aI., 1985) .
As noted above, the neuroprotective effects of bFGF may be related to its ability to attenuate glu tamate-induced increases in calcium. This may be due to a mechanism involving gene transcription, such as an increase in calcium buffering proteins. A direct effect on NMDA receptors is also possible. Recent studies have shown that NMDA receptors can be modulated by protein kinase C, which in creases the probability of opening the NMDA chan nel and reduces the voltage-dependent Mg2 + block of the NMDA-receptor channel (Chen and Huang, 1992) . Another possible mechanism would be ef fects on the neuronal sodium-potassium pump. It has been proposed that the neuroprotective effects of NGF against excitotoxic lesions may be medi ated by actions on the sodium-potassium pump (Schumacher et aI., 1991) . This is consistent with observations that both energy depletion and inhib itors of the sodium-potassium pump increase sus ceptibility to the neurotoxic effects of EAAs in vitro (Novelli et aI., 1988) and in vivo (Beal et aI., 1991; Storey et al., 1992) . Brain-derived neurotrophic fac tor may be able to exert neuroprotective effects by stimulating glutathione production; however, bFGF does not produce this effect (Spina et aI., 1992) .
The precise cellular mechanisms of the neuropro tective effects of bFGF require further investiga tion. Nevertheless, the present study provides the first in vivo evidence that systemic administration of a growth factor can ameliorate neuronal damage induced by both hypoxia-ischemia and EAAs. bFGF has previously been shown to protect against neuronal damage induced by I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (Otto and U nsicker, 1990), which is used to model Parkinson's disease, and NGF shows promise as a neuroprotective agent in Alzheimer's disease (Hefti, 1986) . The present study suggests that administration of bFGF may represent a novel therapeutic strategy for the treat ment of both stroke and neurodegenerative dis eases.
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